Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03080883 · ClinicalTrials.gov registry record · Phase 3
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
A Phase 3 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
NCT03080883 is a Phase 3 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 370 participants.
The verdict
NCT03080883, a Phase 3 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
Study Summary
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy. Apixaban may help in prevention by blocking some of the enzymes needed for venous thrombosis.
Interventions
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2025-05-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03080883
The ClinicalTrials.gov registry entry for NCT03080883 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apixaban is the first listed.
NCT03080883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03080883 about?
NCT03080883 is a clinical study titled "Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy". This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy. Apixaban may help in prevention by blocking some of the enzymes needed for venous thrombosis...
What is the current status of trial NCT03080883?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2017-07-14. Estimated completion is 2025-05-09.
What interventions are being tested in trial NCT03080883?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT03080883?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.